Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome

Transplantation

Volumn 97, Issue 5, 2014, Pages 595-601

  Reinsmoen, Nancy L ^a   Lai, Chih Hung ^a   Mirocha, James ^a   Cao, Kai ^b   Ong, Geraldine ^a   Naim, Mehrnoush ^a   Wang, Qi ^a   Haas, Mark ^a   Rafiei, Matthew ^a   Czer, Lawrence ^a   Patel, Jignesh ^a   Kobashigawa, Jon ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiotensin type 1 receptor antibodies; Antibody mediated rejection; Donor HLAYspecific antibody; Non HLAYspecific antibodies; Transplant vasculopathy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTIBODY; HLA ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CARDIAC GRAFT REJECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT SURVIVAL; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL TIME;

ANTIBODIES; ANTIBODY SPECIFICITY; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNE TOLERANCE; INCIDENCE; KAPLAN-MEIER ESTIMATE; RECEPTOR, ANGIOTENSIN, TYPE 1; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION;

EID: 84896315344     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000436927.08026.a8     Document Type: Article

References (47)

1. Terasaki PI, Cai J. Humoral theory of transplantation: Further evidence. Curr Opin Immunol 2005; 17: 541
2. Kobashigawa J. Contemporary concepts in non-cellular rejection. Heart Fail Clin 2007; 3: 11
3. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of De novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157
4. Everly MJ, Everly JJ, Arend LJ, et al. Reducing De novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063
5. Porcheray F, DeVito J, Helou Y, et al. Expansion of polyreactive B cells cross-reactive to HLA and self in the blood of a patient with kidney graft rejection. Am J Transplant 2012; 12: 2088
6. Briggs D, Zehnder D, Higgins RM. Development of non-donorYspecific HLA antibodies after kidney transplantation: Frequency and clinical implications. Contrib Nephrol 2009; 162: 107
7. Hourmant M, Cesbron-Gautier A, Teresaki PI, et al. Frequency and clinical implications of development of donor-specific and nonY donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804
8. Dragun D. Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation. Transplantation 2008; 86: 1019
9. Dragun D, Philippe A, Catar R. Role of non-HLA antibodies in organ transplantation. Transplantation 2012; 17: 440
10. Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-Angiotension type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90: 1473
11. Dragun D. The role of angiotensin II type 1 receptorYactivating antibodies in renal allograft vascular rejection. Pediatr Nephrol 2007; 22: 911
12. Slowinski T, Suker D, Schonemann C. Screening of patients on waiting-list for a renal transplant for agonistic non-HLA antibodies targeting angiotension II type 1 receptor [abstract]. J Am Soc Nephrol 2006; 17: 393A.
13. Dragun D,Muller DN, Brasen JH, et al. Angiotension II type 1-receptor activating antibodies in renal-Allograft rejection. N Engl J Med 2005; 352: 558
14. Kelsch R, Everding AS, Kuwertz-Broking E, et al. Accelerated kidney transplant rejection and hypertensive encephalopathy in a pediatric patient associated with antibodies against angiotensin type 1 receptor and HLA class II. Transplantation 2011; 92: 57
15. Yousufuddin M, Cook DJ, Starling RC, et al. Angiotensin II receptors from peritransplantation through first-year-post-Transplantation and the risk of transplant coronary artery disease. J Am Coll Cardiol 2004; 43: 1565
16. Yamani MH, Cook DJ, Rodriguez ER, et al. Increased expression of angiotensin II type 1 receptor (AGTR1) in heart transplant recipients with recurrent rejection. J Heart Lung Transplant 2006; 25: 1283
17. Hiemann NE, Meyer R, Wellnhofer E, et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012; 94: 919
18. Reinsmoen NL. Role of angiotensin II type 1 receptorYactivating antibodies in solid organ transplantation. Hum Immunol In press
19. Zou Y, Stastny P. Screening for antibodies against MICA by Luminex flow cytometry. Methods Mol Biol 2012; 882: 279
20. Sumitran-Holgersson S,Wilczek HE, Holgersson J, et al. Identification of the nonclassical HLA molecules, MICA, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002; 74: 268
21. Zou Y, Heinemann FM, Grosse-Wilde H, et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-Transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006; 67: 230
22. Rodriguez-Mahou M, Salcedo M, Fernandez-Cruz E, et al. Antibodies against glutathione S-Transferase T1 (GSTT1) in patients with GSTT1 null genotype as prognostic marker: Long-Term follow-up alter liver transplantation. Transplantation 2007; 83: 1126
23. Aguilera I, Alvarez-Marquez A, Gentil MA, et al. AntiYglutathione S-Transferase T1 antibodyYmediated rejection in C4d-positive renal allografts recipients. Nephrol Dial Transplant 2008; 23: 2393
24. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-Associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886
25. Carter V, Shenton BK, Jaques B. Vimentin antibodies: A non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc 2005; 37: 654
26. Rose ML. Role of MHC and non-MHC antibodies in graft rejection. Curr Opin Organ Transplant 2004; 9: 16
27. Praprotnik S, Blank M, Meroni PL, et al. Classification of antiY endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells. Arthritis Rheum 2001; 44: 1484
28. Joosten SA, Sijpkens YW, van Ham V, et al. Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 2005; 5: 383
29. Forman JP, Lin J, Pascual M, Denton MD, et al. Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation. Am J Transplant 2004; 4: 1786
30. Warraich RS, Pomerance A, Stanley A, et al. Cardiac myosin autoantibodies and acute rejection after heart transplantation in patients with dilated cardiomyopathy. Transplantation 2000; 69: 1609
31. Cardinal H, Dieude M, Brassard N, et al. Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury. Am J Transplant 2013; 13: 861
32. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic antibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103: 945
33. Riemekasten G, Philippe A, Nather M, et al. Involvement of functional auto-Antibodies against vascular receptors in systematic sclerosis. Ann Rheum Dis 2011; 70: 530
34. Amico P, Honger G, Bielmann D, et al. Incidence and prediction of early antibody-mediated rejection due to nonYhuman leukocyte antigen-Antibodies. Transplantation 2008; 85: 1557
35. Berry JG, Angelini A, Burke MM, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: Evolution and current status (2005-2011). J Heart Lung Transplant 2011; 30: 601
36. Dragun D, Catar R, Kusch A, et al. Non-HLA-Antibodies targeting angiotensin type 1 receptor and antibody mediated rejection. Hum Immunol 2012; 73: 1282
37. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56
38. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561
39. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37: 1047
40. Miller JA, Scholey JW. The impact of renin-Angiotensin polymorphisms on physiological and pathophysiological processes in humans. Curr Opin Nephrol Hypertens 2004; 13: 101
41. Hiemann NE, Wellnhofer E, Knosalla C, et al. Prognostic impact of microvasculopathy on survival after heart transplantationVevidence from 9713 endomyocardial biopsies. Circulation 2007; 116: 1274
42. Hiemann NE, Musci M, Wellnhofer E, et al. Light microscopic biopsy findings after heart transplantation and possible links to development of graft vessel disease. Transplant Proc 1999; 31: 149
43. Locke JE, Zachary AA, Warren DS, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLAspecific antibody. Am J Transplant 2009; 9: 2136
44. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al. Role of reninangiotensin system in vascular disease. Hypertension 2001; 38: 1382
45. Nath DS, Basha HI, Mohanakumar T. Antihuman leukocyte antigen antibodyYinduced autoimmunity: Role in chronic rejection. Curr Opin Organ Transplant 2010; 15: 16
46. Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86: 820
47. Lai CH, Cao K, Ong G, et al. Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation 2011; 92: 1